ClinicalTrials.gg
RecruitingNCT05977023Updated Oct 23, 2026

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder

A Phase 2 interventional study of NMDAE and Placebo Cap in Bipolar I Disorder, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Bipolar Disorder with a site in Taiwan — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · Taiwan.

Planned enrollment
17th of 26
90 · median 173
Started
2023
the only one that year
Phase 2
2 of 28
1 open now
Registered
27th of 28
by date
Lead sponsor
1 of 28
China Medical University Hospital

Among the 28 studies in Bipolar Disorder with a site in Taiwan, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 2, and was the 27th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 28 studies in Bipolar Disorder with a site in Taiwan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Bipolar Disorder with a site in Taiwan, or all of them as a file.
02

Study summary

At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.

Read the detailed description

Bipolar I disorder (BD-I) is a severe brain disorder. At present, the treatment of BD-I, especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.

The subjects are bipolar depression patients. They have been treated for bipolar depression for at least four weeks but remain depressive. Participating in this study, they will continue the original treatment, and will be randomized, double-blindly to receive the NMDAE or placebo for 8 weeks. We will measure 6 cognitive domains (including 9 cognitive tests) and quality of life at weeks 0 and 8; and assess the Perceived Stress Scale, Global Assessment of Function (GAF), various scales for clinical symptoms, and side effects at weeks 0, 2, 4, 6, and 8.

The efficacies of NMDAE and placebo will be compared. Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

03

Conditions studied

  • Bipolar I Disorder

Browse trials for

Keywords

  • Bipolar I disorder
  • Bipolar depression
  • NMDA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 to 65 years of age;
  • Satisfy a (American Psychiatric Association) diagnosis of BD-I, current episode depressed, after treatment of stable (i.e., at least 4 weeks) and adequate treatment of antipsychotic (quetiapine or lurasidone) and/or mood stabilizer;
  • Have a 17-item Hamilton Depression Rating Scale (HAMD) score ≥18 and a Young Mania Rating Scale (YMRS) score ≤7 at baseline;
  • Agree to participate in the study and provide

Exclusion criteria

Exclusion Criteria:

  • Current substance abuse or history of substance dependence in the past 6 months
  • History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
  • Schizophrenia or other psychotic disorder
  • Moderate-severe suicidal risks
  • Severe cognitive impairment
  • laboratory screening tests (including blood routine, biochemical tests)
  • Pregnancy or lactation;
  • Inability to follow protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    NMDAE

    An NMDA enhancer

    Drug: NMDAE

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo Cap

Interventions

  • DrugNMDAE

    Use of an NMDA enhancer for the treatment of bipolar depression

  • DrugPlacebo Cap

    Use of placebo as a comparator.

06

What researchers measure

Primary outcomes

  1. Change in Visual Continuous Performance Test

    Assessment of sustained attention

    Time frame: week 0, 8

  2. Change in Wisconsin Card Sorting Test

    Assessment of abstract and shift set

    Time frame: week 0, 8

  3. Change in Logical Memory Test of the Wechsler Memory Scale

    Assessment of episodic memory

    Time frame: week 0, 8

  4. Digit Span

    Assessment of verbal working memory

    Time frame: week 0, 8

  5. Spatial Span

    Assessment of nonverbal working memory

    Time frame: week 0, 8

  6. Category Fluency

    Assessment of speed of processing

    Time frame: week 0, 8

  7. Trail Marking A

    Assessment of speed of processing

    Time frame: week 0, 8

  8. WAIS-III Digit Symbol-Coding

    Assessment of speed of processing

    Time frame: week 0, 8

  9. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0

    Assessment of social cognition

    Time frame: week 0, 8

  10. Change in Perceived Stress Scale in Perceived Stress Scale

    Assessment of stress and anxiety symptoms Minimum value: 0, maximum value:56, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

Secondary outcomes

  1. Change in Quality of life (SF-36)

    Time frame: week 0, 8

  2. Change in Global Assessmeint of Functioning

    Assessment of global improvement. Minimum value: 1, maximum value:100, the higher scores mean a better outcome.

    Time frame: Week 0, 2, 4, 6, 8

  3. Change in Hamilton Rating Scale for Depression

    Assessment of depressive symptoms. Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.

    Time frame: Week 0, 2, 4, 6, 8

  4. Change in Montgomery-Åsberg Depression Rating Scale

    Assessment of depressive symptoms. Minimum value: 0, maximum value:60, the higher scores mean a worse outcome.

    Time frame: Week 0, 2, 4, 6, 8

  5. Change in Young Mania Rating Scale

    Assessment of manic symptoms. Minimum value: 0, maximum value:60, the higher scores mean a worse outcome.

    Time frame: Week 0, 2, 4, 6, 8

  6. Change in Beck Scale for Suicide Ideation

    Assessment of Suicide Ideation. Minimum value: 0, maximum value:38, the higher scores mean a greater risk of suicide.

    Time frame: Week 0, 2, 4, 6, 8

  7. Change in Clinical Global Impression Scale

    Time frame: Week 0, 2, 4, 6, 8

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 49 months after the start.

Of 42 non-industry phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 49 months is close to that.

Counting every sponsor, half of 56 studies reached it within 33 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 4, 2023
StartActual
Oct 4, 2023
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and index terms
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05977023
Collaborators
National Science and Technology Council
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Oct 4, 2023
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Hsien-Yuan Lane Lane, M.D., Ph.D
Contact
hylane@gmail.com
886 4 22052121 ext. 1855

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion